At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular therapy.

This is the online version of STAT's email newsletter Health Care Inc, delivered to your inbox every Monday. Sign up here. ...

The overture to the American Heart Association’s conference, coming as the organization celebrates its 100th year, began with ...

Today's health news includes how RFK Jr. could strip legal protections from vaccine makers and why more young people are getting cancer.

Robert F. Kennedy Jr. would have broad power as HHS secretary to strip vaccine makers' protections against lawsuits ...

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

Based on a small trial with positive muscle performance data, Regenxbio is expected to pursue approval of its gene therapy ...

Republicans have despised the Affordable Care Act since its inception almost 15 years ago. But some health care executives ...

Nothing brought Olivia more joy than when her daughter and grandchild visited her group home in Brooklyn in the early 2000s.

CHICAGO — In his presidential address to the American Heart Association on Sunday, Keith Churchwell, a clinical cardiologist ...

Cancer cases are on the rise among people under 50 — and researchers aren’t sure why. A recent study by the American Cancer ...

The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a ...